Septerna, Inc.
Financials
Valuation Metrics
Septerna, Inc.'s Market Cap is $2.05B. At end of 2025 it was $1.23B. Ranked #1997 of 3,115 in US market (top 64%), #754 of 1,472 on NASDAQ (top 51%), #135 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.05B | US#1,997/3,115 Sec#135/265 |
| Revenue | $99M | US#2,675/3,115 Sec#124/265 |
| Net Income | $-24M | US—/3,115 Sec—/265 |
| Total Assets | $567M | US#2,716/3,115 Sec#147/265 |
| Net Assets | $387M | US#2,381/3,115 Sec#136/265 |
| Employees | 123 | US#2,578/3,115 Sec#162/265 |
| Value | ||
| P/B | 5.31x | US#2,238/3,115 Sec#149/265 |
| P/S | 20.75x | US#2,851/3,115 Sec#143/265 |
| FCF Yield | 5.12% | US#1,308/3,115 Sec#41/265 |
| Profitability | ||
| ROE | -6.27% | US#2,287/3,115 Sec#74/265 |
| ROA | -4.28% | US#2,491/3,115 Sec#85/265 |
| Op. Margin | -44.04% | US#2,648/3,115 Sec#109/265 |
| Revenue Growth | 13520.11% | US#5/3,115 Sec#3/265 |
| Financial Health | ||
| Debt Ratio | 46.55% | US#530/3,115 Sec#137/265 |
| Total Debt | $23M | US#2,736/3,115 Sec#184/265 |
| FCF | $105M | US#1,708/3,115 Sec#62/265 |
| Cash | $85M | US#2,320/3,115 Sec#185/265 |
| Current Ratio | 4.99x | US#467/3,115 Sec#144/265 |
| Performance | ||
| 1Y Return | 104.56% | US#201/3,115 Sec#41/265 |
| 1M Return | 12.34% | US#567/3,115 Sec#35/265 |
| From 52W High | -13.97% | US#1,381/3,115 Sec#67/265 |
| 1Y MDD | -25.98% | US#1,013/3,115 Sec#47/265 |
| Trading | ||
| Volume | 177,096 shares | US#2,406/3,115 Sec#235/265 |
| Trading Value | $8M | US#2,154/3,115 Sec#168/265 |
| Per Share | ||
| EPS | $-0.52 | US—/3,115 Sec—/265 |
| BPS | $8.29 | US#1,960/3,115 Sec#82/265 |
Company Info
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.